Q-omics provides the consensus-scored PPP4R2 profile across patient tissues and cancer cell-line models. PPP4R2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, PPP4R2 is differentially expressed in 9, with the highest sampling consensus in STAD. Additionally, PPP4R2 protein abundance shows 28,403 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, STAD, and GBM as cancer lineages where PPP4R2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP4R2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP4R2 survival associations across molecular data types. PPP4R2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP4R2 RNA expression–survival associations across cancer types. High PPP4R2 expression shows unfavorable associations in LGG and SARC, but favorable associations in BRCA, SKCM, UCEC and UCS. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for PPP4R2 RNA expression.
This table summarizes PPP4R2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PPP4R2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP4R2 shows lower tumor expression in KIRC and THCA and higher tumor expression in STAD, BLCA, LIHC and LUAD. The STAD box plot shows higher PPP4R2 RNA expression in tumor versus normal tissue (log2 FC = +0.699, t-test p < 0.001).
This table shows molecular features associated with PPP4R2 in patient tissues and cancer cell lines. In patient samples, PPP4R2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP4R2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
